Organon signs an exclusive, worldwide licence agreement on advanced antithrombotic compounds with Endotis Pharma
Organon, the human healthcare business unit of Akzo Nobel, announced that it has signed an exclusive, worldwide license agreement with Endotis Pharma concerning the development and commercialization of several antithrombotic compounds. Endotis is a specialty pharma company dedicated to the discovery and development of small-glyco drugs for applications in thrombosis and oncology.
Under the terms of the agreement, Endotis has acquired exclusive rights to develop and commercialize Org 42675, Org 217609 (a neutralizable follow-up of Org 42675) and Org 224283, three antithrombotic compounds with an innovative dual mechanism of action. Financial details are not disclosed.
Org 42675 and Org 217609 display a new and original dual mechanism of action, combining blood coagulation factor Xa inhibition and thrombin inhibition. Org 42675 has successfully completed two phase I clinical trials. Org 224283 also displays an innovative dual mechanism of action, combining factor Xa inhibition and an antiplatelet effect, both effects being neutralizable by a specific antidote. Org 224283 is at a preclinical-stage of development.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.